At Polpharma Biologics, our commitment to excellence begins at the top. With decades of combined experience at some the world largest pharmaceutical companies our advisory board brings immense expertise.
Mark McCamis is an international expert in biologics and biosimilars development and manufacturing - he led pioneering efforts in filing/launching biosimilars worldwide. Mark is a senior executive with extensive experience at multiple companies including Abbott, Amgen, Novartis/Sandoz.
Wolf is an Advisory Board Member of Polpharma Biologics S.A. Wolf has over 40 years of experience in Biotech specifically the physical drug development of pharma proteins. Since 2011, he works also as president of his own strategy of CMC biotech consulting company (bbphc GmbH) helping large biopharma in innovation technologies.
Hans Peter Hasler
Hans Peter Hasler joined the Polpharma Biologics Advisory Board in May 2020. He is an advisor to Pharma-/Biotech firms globally and owner of HPH Management GmbH, Kuessnacht, Switzerland. Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland and Chairman of the Board of Shield Therapeutics, London.